Cancer immunotherapy research is expanding beyond established biomarkers, such as PD-L1 expression and TMB, to explore neoantigen profiles, circulating tumor DNA, and immune cell infiltration patterns within the tumor microenvironment (Figure 6). This evidence concerns the gene CD274 and neoplasm.